Search Result

Results for "

ALK2 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) AMPK (2) Anaplastic lymphoma kinase (ALK) (7) Apoptosis (1) Autophagy (4) c-Kit (1) Casein Kinase (1) CDK (1) Checkpoint Kinase (Chk) (1) EGFR (1) FLT3 (2) JAK (2) mTOR (2) Organoid (5) PI3K (2) Pim (1) RIP kinase (3) STAT (2) TGF-beta/Smad (3) TGF-β Receptor (29) Trk Receptor (1)
By Research Areas:	Cancer (26) Cardiovascular Disease (2) Inflammation/Immunology (4) Metabolic Disease (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112815

ALK2-IN-2 1 Publications Verification	TGF-β Receptor	Cardiovascular Disease Inflammation/Immunology
ALK2-IN-2 is an orally active and selective inhibitor of *ALK2* (ACVR1), with an IC₅₀ value of 9 nM, and over 700-fold selectivity against ALK3. ALK2-IN-2 can inhibit oxidative stress and protect endothelial cells .

HY-136773

KER047 ALK2-IN-4	TGF-β Receptor	Metabolic Disease
ALK2-IN-4 is a potent *ALK2* inhibitor extracted from patent WO2020086963A1, compound Formula I free base .

HY-136773A

KER047 succinate ALK2-IN-4 succinate	TGF-β Receptor	Metabolic Disease
ALK2-IN-4 succinate is a potent *ALK2* inhibitor extracted from patent WO2020086963A1, compound Formula I free base .

HY-19628

OD36	RIP kinase TGF-β Receptor	Inflammation/Immunology
OD36 is a RIPK2 inhibitor with an IC₅₀ of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the *ALK2* kinase ATP pocket. OD36 shows ALK2-directed activity with K_Ds of 37 nM .

HY-148234

M4K2234	Anaplastic lymphoma kinase (ALK)	Cancer
M4K2234 (compound 26b) is an *ALK2* inhibitor. M4K2234 inhibits ALK2 and ALK5 with IC₅₀s of 5 and 2144 nM, respectively. M4K2234 can be used as a chemical probe for ALK1 and ALK2 protein kinases. M4K2234 can be used for the research of cancer .

HY-167864

M4K2308	TGF-β Receptor	Cancer
M4K2308 is a selective ether-linked inhibitor of *ALK2* with an IC₅₀ of 2 nM. M4K2308 exhibits exceptional selectivity for ALK2 over ALK5 (IC₅₀ of 224 nM). M4K2308 has the potential for the study of diffuse intrinsic pontine glioma (DIPG) research .

HY-153246

ALK2-IN-5	Anaplastic lymphoma kinase (ALK)	Cancer
ALK2-IN-5, pyrazolopyrimidine compound, is an *ALK2* inhibitor. ALK2-IN-5 can inhibit ALK2 activity and FGFR activity. ALK2-IN-5 can be used for the research of disorders associated with ALK2 activity and/or FGFR activity, such as cancer .

HY-155939

M4K2163 dihydrochloride	TGF-β Receptor	Cancer
M4K2163 dihydrochloride is a potent, selective, blood-brain barrier (BBB) permeable activin receptor-like kinase-2 (ALK2) inhibitor, with an IC₅₀ of 19 nM. M4K2163 dihydrochloride can be used in the research of diffuse intrinsic pontine glioma (DIPG) .

HY-151273

ALK5-IN-27	TGF-β Receptor	Cancer
ALK5-IN-27 (Compound EX-04) is a potent ALK-5 inhibitor with an IC₅₀ ≤10 nM. ALK5-IN-27 also inhibits *ALK-2* (selectivity ALK2/ALK5 ≤10) .

HY-19628A

OD36 hydrochloride	RIP kinase TGF-β Receptor	Inflammation/Immunology
OD36hydrochloride is a RIPK2 inhibitor with an IC₅₀ of 5.3 nM. OD36 hydrochloride is a macrocyclic inhibitor with potent binding to the *ALK2* kinase ATP pocket. OD36 hydrochloride shows ALK2-directed activity with K_Ds of 37 nM .

HY-117887

Fidrisertib BLU-782; IPN-60130; ALK2-IN-1	TGF-β Receptor	Cancer
Fidrisertib (BLU-782) is the orally active inhibitor for activin receptor-like kinase 2 (ALK2) that inhibits ALK2 ^R206H, *ALK2, ALK1, ALK6, ALK3, ALK4, TGFβR2* and ALK5 with IC₅₀s of 0.2, 0.6, 3, 24, 45, 65, 67 and 155 nM, respectively .

HY-151270

ALK5-IN-25	TGF-β Receptor	Cancer
ALK5-IN-25 (compound EX-02) is a potent ALK-5 inhibitor with an IC₅₀ ≤10 nM.ALK5-IN-25 also inhibits *ALK-2* (selectivity ALK2/ALK5≤10). ALK5-IN-25 can be used for the research of cancer .

HY-173149

CDD-2789	Anaplastic lymphoma kinase (ALK) TGF-beta/Smad TGF-β Receptor	Cancer
CDD-2789 is a highly selective small-molecule inhibitor targeting Activin receptor type 1 (ALK2, also known as ACVR1). It blocks the SMAD1/5 signaling pathway mediated by *ALK2/ALK1, thereby effectively suppressing downstream phosphorylation events induced by BMP* and activin A. In the NanoBRET cellular model, CDD-2789 exhibits an inhibitory IC₅₀ of 0.54 µM against *ALK2. CDD-2789 holds promise for research on ALK2*-related diseases, including diffuse intrinsic pontine glioma (DIPG), ependymoma, endometrial cancer, melanoma, non–small cell lung cancer, colorectal cancer, and pancreatic cancer .

HY-12274

ML347 5+ Cited Publications LDN 193719	TGF-β Receptor	Cancer
ML347 (LDN193719) is a highly selective *ALK1/ALK2* inhibitor. ML347 has IC₅₀ values of 46 and 32 nM against ALK1 and ALK2, respectively, >300-fold selective over ALK3. ML347 block the phosphorylation of Smad1/5 by TGF-β1 .

HY-16712

LDN-214117 1 Publications Verification	TGF-β Receptor	Cancer
LDN-214117 is an orally active *ALK2* inhibitor with well-tolerated and good brain penetration. LDN-214117 has a high selectivity and low cytotoxicity for ALK2 with an IC₅₀ value of 24 nM. LDN-214117 also is a specific bone morphogenetic proteins (BMPs) signaling inhibitor and has relatively selective inhibition for BMP6 with an IC₅₀ value of 100 nM. LDN-214117 can be used for the research of fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma (DIPG) ^[2]

HY-12273

DMH-1 5+ Cited Publications	Autophagy TGF-β Receptor	Cancer
DMH-1 is a potent and selective BMP inhibitor with IC₅₀s of 27/107.9/<5/47.6 nM for ALK1/ALK2/ALK3/ALK6, respectively.

HY-109179A

Itacnosertib hydrochloride TP-0184 hydrochloride	JAK Anaplastic lymphoma kinase (ALK) FLT3 STAT PI3K Akt mTOR TGF-beta/Smad TGF-β Receptor	Cancer
Itacnosertib hydrochloride (TP-0184 hydrochloride) is the inhibitor for FLT3, ACVR1 (ALK2, IC₅₀=8 nM) and JAK2 (IC₅₀=8540 nM). Itacnosertib hydrochloride exhibits anti-leukemic activity .

HY-109179

Itacnosertib TP-0184	JAK Anaplastic lymphoma kinase (ALK) FLT3 STAT PI3K Akt mTOR TGF-beta/Smad TGF-β Receptor	Cancer
Itacnosertib (TP-0184) is the inhibitor for FLT3, ACVR1 (ALK2, IC₅₀=8 nM) and JAK2 (IC₅₀=8540 nM). Itacnosertib exhibits anti-leukemic activity .

HY-161377

M4K2306	TGF-β Receptor	Cancer
M4K2306 is a selective inhibitor for activin receptor-like kinase-2 (ALK2) with an IC₅₀ of 7 nM. M4K2306 is blood brain permeable with a brain to plasma ratio of 75.6 .

HY-12273R

DMH-1 (Standard)	Autophagy TGF-β Receptor	Cancer
DMH-1 (Standard) is the analytical standard of DMH-1. DMH-1 is a potent and selective BMP inhibitor with IC₅₀s of 27/107.9/<5/47.6 nM for ALK1/ALK2/ALK3/ALK6, respectively.

HY-161376

M4K2281	TGF-β Receptor	Cancer
M4K2281 is a selecitve inhibitor for activin receptor-like kinase-2 (ALK2) with an IC₅₀ of 2 nM. M4K2281 exhibits a moderate blood brain permeability with a brain to plasma ratio of 3.7 at 4h .

HY-12071A

LDN193189 Tetrahydrochloride 65+ Cited Publications DM-3189 Tetrahydrochloride	Organoid TGF-β Receptor	Cancer
LDN193189 Tetrahydrochloride is a selective BMP type I receptor inhibitor, which efficiently inhibits *ALK2* and ALK3 (IC₅₀=5 nM and 30 nM, respectively), with weaker effects on ALK4, ALK5 and ALK7 (IC₅₀≥500 nM) .

HY-13418

Dorsomorphin dihydrochloride Maximum Cited Publications 565 Publications Verification Compound C dihydrochloride; BML-275 dihydrochloride	Organoid AMPK TGF-β Receptor Autophagy	Cancer
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a K_i of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors *ALK2, ALK3, and ALK6*. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).

HY-145608

Zilurgisertib INCB-000928; NBU-928	TGF-β Receptor	Cardiovascular Disease Cancer
Zilurgisertib (INCB-000928; NBU-928) is a selective *ALK2* inhibitor with an IC₅₀ value of 15 nM. Zilurgisertib inhibits SMAD1/5 phosphorylation with an IC₅₀ value of 63 nM. Zilurgisertib inhibits hepcidin production and improve anemia. Zilurgisertib can be used in melanoma research .

HY-15897

LDN-212854 1 Publications Verification	TGF-β Receptor	Cancer
LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits *ALK2* (IC₅₀: 1.3 nM). LDN-212854 also inhibits ALK1 (IC₅₀: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC) .

HY-19928A

Vactosertib Hydrochloride 5+ Cited Publications EW-7197 Hydrochloride; TEW-7197 Hydrochloride	TGF-β Receptor	Cancer
Vactosertib Hydrochloride (EW-7197 Hydrochloride) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib Hydrochloride has potently antimetastatic activity and anticancer effect .

HY-19928

Vactosertib 5+ Cited Publications EW-7197; TEW-7197	TGF-β Receptor	Cancer
Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect .

HY-146694

RIPK2-IN-1	RIP kinase Anaplastic lymphoma kinase (ALK)	Inflammation/Immunology
RIPK2-IN-1 (compound 18f) is a potent RIPK2 inhibitor with an IC₅₀ of 51 nM. RIPK2-IN-1 inhibits *ALK2* with an IC₅₀ of 5 nM. RIPK2-IN-1 has an IC₅₀ of 390 nM on RIPK2/NOD2 in cell assay .

HY-13418A

Dorsomorphin Maximum Cited Publications 565 Publications Verification Compound C; BML-275	Organoid AMPK TGF-β Receptor Autophagy	Cancer
Dorsomorphin (Compound C) is a selective and ATP-competitive AMPK inhibitor (K_i=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors *ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy* activation and anti-inflammatory effect of Urolithin A (HY-100599) .

HY-12278

K02288 3 Publications Verification	TGF-β Receptor	Others
K02288 is a potent bone morphogenetic protein (BMP) type I receptor inhibitor with IC₅₀s of 1.8, 1.1, 6.4 nM for ALK1, ALK2 and ALK6, respectively. K02288 shows slightly weaker inhibition against ALK3 and ALK6 with IC₅₀s of of 5-34 nM.

HY-12071

LDN193189 65+ Cited Publications DM-3189	Organoid TGF-β Receptor	Cancer
LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors *ALK2* and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .

HY-12071B

LDN-193189 dihydrochloride 65+ Cited Publications DM-3189 dihydrochloride	TGF-β Receptor Organoid	Cancer
LDN-193189 (dihydrochloride) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors *ALK2* and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .

HY-156470

Multi-kinase-IN-6	Trk Receptor Anaplastic lymphoma kinase (ALK) c-Kit EGFR Pim Casein Kinase Checkpoint Kinase (Chk) CDK Apoptosis	Cancer
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that shows good enzyme inhibitory activity against TrkA, *ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. Multi-kinase-IN-6 reveals antiproliferative activity against MCF7, HCT116 and EKVX with IC₅₀* values of 3.36 μM, 1.40 μM and 3.49 μM, respectively. Multi-kinase-IN-6 shows cell cycle arrest at the G1/S phase and G1 phase in MCF7 and HCT116 cells with good apoptotic effect .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

ALK2 inhibitor

Inhibitors & Agonists